ClinicalTrials.gg
RecruitingNCT07193069Updated Sep 25, 2025

Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning

An observational study in Drug Overdose, Metformin and Dapagliflozin, sponsored by Centre Hospitalier de Saint-Denis. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by Centre Hospitalier de Saint-Denis · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

This study looks at patients admitted to intensive care for drug poisoning involving metformin, a common diabetes medication. Researchers will compare two groups: patients who overdosed on metformin alone and those who took both metformin and dapagliflozin, another diabetes drug. The goal is to find clinical or laboratory signs that could help doctors quickly recognize a dapagliflozin overdose in this context, which could improve treatment and patient outcomes.

02

Conditions studied

  • Drug Overdose
  • Metformin
  • Dapagliflozin
  • Lactic Acidosis
  • Diabetic Ketoacidosis
  • Intensive Care Units
03

In context

Drug Overdose

104 studies on the registry are indexed under Drug Overdose; 22 are open to participants now.

This study's planned enrollment of 50 is below the median of 450 across 26 observational studies indexed under Drug Overdose.

Browse Drug Overdose studies →

Lead sponsor

Centre Hospitalier de Saint-Denis is the lead sponsor of 46 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population will consist of adult patients (aged 18 years and older) who were admitted to intensive care units across multiple centers for acute drug poisoning involving metformin, with or without dapagliflozin. Participants will be identified retrospectively through case collection from the SRLF (Société de Réanimation de Langue Française) and existing hospital records over the past 10 years. The study will include both cases of isolated metformin overdose and cases of combined metformin and dapagliflozin overdose.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older
  • Admission to an intensive care unit (ICU) due to acute drug poisoning
  • Documented exposure to either:
  • Metformin alone
  • Metformin in combination with dapagliflozin

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years of age
  • No exposure to metformin
  • Exposure to dapagliflozin without metformin
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Identification of clinical and biological differences between patients admitted to intensive care for metformin overdose alone versus those with combined metformin and dapagliflozin overdose.

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Apr 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Sep 25, 2025
StartActual
Apr 11, 2025
Primary completionEst.
Apr 11, 2026
CompletionEst.
Apr 11, 2026
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07193069
Lead sponsor
Centre Hospitalier de Saint-Denis
Responsible party
Sponsor
First posted
Sep 25, 2025
Start date
Apr 11, 2025
Primary completion
Apr 11, 2026 (estimated)
Completion
Apr 11, 2026 (estimated)
Last update
Sep 25, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion